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Abstract
Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not re-
spond well to standard RA treatment. Leflunomide therapy may, however, be related with significant pulmonary complications 
in predisposed individuals. We present a patient with RA treated with leflunomide, in whom leflunomide lung injury had a fatal 
outcome. Potential risk factors for pulmonary complications of leflunomide treatment and the  management  of patients with 
leflunomide lung injury are discussed.
Key words: interstitial pneumonia, rheumatoid arthritis, leflunomide 
Pneumonol. Alergol. Pol. 2015; 83: 50–54
Streszczenie
Leflunomid należy do leków przeciwreumatycznych modyfikujących przebieg choroby. Jest on stosowany u chorych z reumato-
idalnym zapaleniem stawów, u których leczenie pierwszej linii było nieskuteczne. Leczenie leflunomidem może być jednak zwią-
zane z istotnymi powikłaniami płucnymi, zwłaszcza u osób predysponowanych. Autorzy przedstawiają opis przypadku chorego 
na reumatoidalne zapalenie stawów leczonego leflunomidem, u ktorego wystąpiły powikłania ze strony układu oddechowego. 
Omówiono czynniki ryzyka wystąpienia uszkodzenia płuc w  przebiegu leczenia tym preparatem oraz sposób postępowania 
w przypadku ich wystąpienia.
Słowa kluczowe: choroba śródmiąższowa płuc, reumatoidalne zapalenie stawów, leflunomid
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Introduction
Rheumatoid arthritis (RA) is a systemic disease 
that frequently involves the respiratory system. 
Interstitial lung disease (ILD) is one of the leading 
causes of RA-related mortality [1]. Disease-modifying 
anti-rheumatic drugs (DMARDs) have been shown to 
have a positive impact on the course of the disease. 
Leflunomide, a DMARD introduced more 
than a decade ago, was reported to alleviate RA 
symptoms and retard radiological progression of 
the disease [2]. However, adverse-event moni-
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toring revealed an increased risk of interstitial 
lung disease in predisposed individuals. These 
particularly included subjects with pre-existing 
interstitial lung disease or other lung diseases and 
a history of methotrexate treatment [3].
We present a case of a 54-year-old male with 
a RA-related interstitial lung disease treated with 
leflunomide, who had previously undergone 
methotrexate therapy and who developed rapid 
ILD progression. 
Case report
A 54-year-old male with rheumatoid arthritis 
and a  relevant smoking history (30 packyears) 
was admitted to our department due to rapidly 
progressing dyspnoea and dry cough. Data on the 
course of RA came exclusively from the patient’s 
family and a single discharge card. RA had been 
diagnosed 20 years ago and had been treated with 
methotrexate and steroids. The treatment had 
been withdrawn 6 months previously because of 
the progression of lung fibrosis, and was replaced 
by azathioprine; however, this therapy was also 
terminated due to drug intolerance. Two months 
prior to the present hospitalisation the patient’s 
consulting rheumatologist decided to initiate 
leflunomide therapy at a daily dosage of 20 mg, 
and the patient had been receiving leflunomide 
up to the day of admission. 
On admission the patient was in a severe ge-
neral condition, afebrile, with tachypnoe 29/min, 
heart rate 100/min, and blood pressure 100/80 
mm Hg. On auscultation, crackles in the middle 
and basal lung areas were found. The analysis of 
arterial blood gases revealed hypoxaemia (PaO2 
42.1 mm Hg) and hypocapnia (PaCO2 23.2 mm 
Hg); other relevant laboratory findings included 
elevated levels of C-reactive protein (259 mg/L, 
normal range 0−10 mg/L), procalcitonin (0.56 ng/
ml, normal range 0−0.5 ng/ml), d-dimer (1888 
ng/mL, normal range 0-500 ng/mL), creatinine 
(1.67 mg/dL, normal range 0.5−1.1) and increased 
activity of troponin (1.88 ng/mL, normal range 
0.0−0.1 ng/mL), transaminases (ALT 172 U/L 
and AST 205 U/L, normal range 7−56 U/L and 
5−40 U/L, respectively), and natriuretic peptide 
(747 pg/mL, normal range 0−125 pg/mL). The 
leukocyte count was normal, but an increased 
neutrophil count and decreased lymphocyte 
count were observed (86.3% and 8.0%, respec-
tively). The remaining laboratory findings were 
unremarkable. The chest radiograph revealed 
bilateral interstitial opacities, more pronounced 
in the left lung. Spiral computed tomography of 
the chest did not confirm pulmonary embolism; 
however, diffuse ground glass opacities in both 
lungs with basal subpleural honeycombing was 
demonstrated, suggesting an active parenchymal 
inflammation (Fig. 1). ECG showed negative T 
waves in the III, aVF, and V1 to V5 leads, echo-
cardiography revealed right ventricle overload, 
tricuspid regurgitation (tricuspid insufficiency 
pressure gradient 55 mm Hg) with right ventri-
cular free wall hypokinesis and an acceleration 
time (AcT) of 80 ms; no abnormal left ventricle 
wall contractility was detected. 
Leflunomide was discontinued. The pa-
tient received oxygen therapy, systemic stero-
ids (intravenous methylprednisolone 62.5 mg 
bid), mucolytics, and antibiotic therapy with 
intravenous amoxicillin/clavulanic acid. As no 
marked improvement was observed within the 
first three days of treatment, co-amoxiclav was 
by replaced by ceftriaxone with co-trimoxazole 
and fluconazole. Serologic tests for Epstein-Barr 
virus, cytomegalovirus, and adeno-, astro-, nora-, 
and rotaviruses were negative. Sputum cultures 
showed physiological upper airway flora; blood 
cultures were negative. 
The modification of antimicrobial treatment 
resulted in five days of stabilisation. However, on 
the 9th day after admission the patient’s condition 
worsened and he required mechanical ventilation. 
The chest radiograph performed at that time sho-
wed progression of the interstitial opacities. The 
dose of methylprednisolone was doubled (250 mg 
once daily) and cyclophosphamide (100 mg 
once daily) was initiated, but no improvement 
Figure 1. CT scan with diffuse ground glass opacities with basal 
subpleural honeycombing in both lungs 
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was noted. The patient died on the 16th day of 
hospitalisation. 
Gross autopsy findings were massive oede-
ma and congestion with fibrosis of the lungs, 
localised mainly in the lower lobes. Microscopic 
features of diffuse alveolar damage were found, 
mostly organising phase with fibrosis of inte-
ralveolar septa. However, foci of active process 
with formation of hyaline membranes were also 
noted. Additionally, foci of invasive (Grocott sta-
in) aspergillosis, haemorrhagic infarcts, lobular 
pneumonia, and acute bronchitis were revealed 
(Fig. 2). 
Discussion 
Respiratory involvement is the second le-
ading cause of mortality in rheumatoid arthritis 
following cardiovascular diseases [1, 4]. Respira-
tory manifestations of RA include the following: 
pulmonary nodules, bronchiectases, bronchioli-
tis, pleural involvement and interstitial lung di-
seases, and, finally, infections related to immuno-
suppressive treatment [5, 6, 7]. The lifetime risk 
of RA-related interstitial lung disease is estimated 
at 7.7% and is related with a  threefold higher 
RA mortality [7]. It is more frequent in males, in 
patients with late RA onset, and increases with 
RA severity. However, for evident reasons, these 
studies were performed in patients receiving RA 
treatment, and the potential lung toxicity of anti
-rheumatic drugs cannot be excluded. 
Leflunomide was licensed for the treatment of 
rheumatoid arthritis more than 10 years ago [8]. 
Since then, surveillance studies have carefully 
analysed its effectiveness and potential side ef-
fects. After alarming reports coming from Japan 
on 5 deaths in 16 RA patients who had received 
this drug [9], lung toxicity remains one of the 
major concerns related to leflunomide therapy. 
Ju et al. found an ILD incidence of 1% in a group 
of 1,010 RA patients treated with leflunomide in 
the Korean population [10]. Similar data were 
reported by Sawada et al., who estimated the 
prevalence of ILD to be 1.2% in Japanese patients 
with RA receiving leflunomide [3]. However, the 
exact relation between leflunomide use and ILD 
occurrence is being discussed. Studies published 
to date do not to clarify whether the increased 
risk of newly developed ILD or exacerbation of 
pre-existing RA-ILD is related to leflunomide itself 
or to RA progression. The authors indicate that 
patients with a history of chronic lung disease, 
pre-existing ILD, and prior methotrexate use are 
at a higher risk of developing ILD during leflu-
Figure 2. Histopathological appearance of the lung; A  — diffuse 
alveolar damage pattern black hyaline membrane formation; B — Gro-
cott stain with evidence of Aspergillus infection (white arrow)
A
B
nomide treatment (Table 1) [3, 10, 11]. Suissa 
et al. found that RA patients without any of the 
above-mentioned risk factors did not have a hi-
gher probability of ILD with leflunomide use [11]. 
Our patient had several risk factors for leflu-
nomide-related ILD: male sex, a relevant smoking 
Table 1.  Factors predisposing to leflunomide-related 
interstitial lung disease in patients with rheuma-
toid arthritis [3, 10, 11]
Risk factors for the development of leflunomide-related  
disease in RA patients
Male sex 
Smoking
Long RA duration 
History of chronic lung disease
Pre-existing interstitial lung disease 
Prior methotrexate use 
Asian origin? 
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history, and long RA duration with a high disease 
activity, which imposed treatment modifications. 
Moreover, he had an eight-year history of RA-ILD 
and had been receiving methotrexate prior to le-
flunomide administration, both of which increase 
the risk of ILD development/exacerbation during 
leflunomide use. The first symptoms of lung inju-
ry appeared after nine weeks of leflunomide thera-
py. This time interval concurs with that reported 
by Chikura et al., who performed an analysis of 
32 cases of leflunomide-induced lung injury and 
demonstrated that this condition usually occurs 
within 20 weeks from the onset of leflunomide 
administration [12]. The time relation between 
ILD progression and leflunomide use, ineffective 
antimicrobial treatment, and lack of evidence for 
viral infection in our patient indicated an asso-
ciation between ILD and leflunomide. 
Leflunomide discontinuation is a cornersto-
ne in the management of leflunomide-induced 
lung injury; however, no particular therapeutic 
algorithm has been established to date. Chikura 
et al. found that 75% of the reviewed cases had 
received steroids, 31% had received antimicro-
bial treatment, and 22% were treated with both 
steroids and antibiotics [12]. The elimination 
of leflunomide may be accelerated by cholesty-
ramine, and this is a very promising treatment 
option [2, 12, 13]. Wong et al. reported a case 
of successful treatment with cholestyramine in 
monotherapy administered orally in a dose of 8 g 
three times daily [14], but further convincing 
data on the efficacy of this drug in the treatment 
of leflunomide-induced lung injury are required. 
In a recent review by R. Raj and K. Nugent, the 
recommended approach is that of leflunomide 
washout with cholestyramine; activated charcoal 
(50 mg every six hours for 24 hours) may also be 
considered to enhance leflunomide elimination. 
Nevertheless, the same authors present data that 
show that leflunomide discontinuation along with 
systemic steroids is the most frequently applied 
treatment [15]. 
Our patient presented a temporary respon-
se to combined therapy with steroids and an-
tibiotics. The initial improvement suggested 
respiratory infection as the underlying cause of 
the patient’s condition, regardless of leflunomide 
discontinuation, as leflunomide is characterised 
by a half-life of 1−4 weeks [14]. That is why 
cholestyramine washout was not applied. The 
treatment had to be verified due to the patient’s 
deterioration after a five-day period of stabili-
ty. We subsequently chose cyclophosphamide, 
which is potentially capable of inhibiting lung 
fibrosis, for add-on therapy as the patient had 
reported azathioprine intolerance. No data on 
the effectiveness of cyclophosphamide in leflu-
nomide-induced lung injury are available. Un-
fortunately, an increase in the steroid dose and 
the addition of cyclophosphamide had no effect. 
Autopsy findings revealed DAD superimpo-
sed on long-standing interstitial lung disease. 
The pathomechanism leading to DAD in our case 
is complex with at least three potential contri-
buting factors: Aspergillus infection, leflunomide 
treatment, and RA itself. Ochi et al. [13] described 
a 75-year-old patient with RA who developed 
acute interstitial pneumonia 45 days after the 
onset of leflunomide therapy, and who had a very 
similar histopathological appearance of the lung, 
including features of Aspergillus infection. The 
probability of pulmonary aspergillosis in our pa-
tient seemed low; the radiological appearance of 
the chest was not typical for invasive Aspergillus 
infection (usually presenting as nodular lesions 
with a rim of ground glass — the so-called “halo 
sign” or the air crescent sign). Sputum cultures 
were negative and the patient’s condition did 
not allow bronchoalveolar lavage, so BAL fluid 
galactomannan and Aspergillus specific PCR 
could not be evaluated. Serum galactomannan 
and 1-D b glucan were not assessed. Of note, 
the sensitivity and specificity of the above-men-
tioned serological and molecular methods in 
the diagnosis of invasive aspergillosis are still 
being discussed [16, 17]. Despite progress in the 
diagnostics of fungal infections, up to 75% of 
invasive fungal diseases are diagnosed in autopsy 
[19]. In our patient, the presence of Aspergillus 
in the lungs causing tissue damage, a definite 
criterion of invasive aspergillosis, was also found 
in autopsy [17]. 
Chikura et al. have shown that there is 50% 
mortality in leflunomide-induced lung injury in 
patients with pre-existing RA-ILD [12]. According 
to Saito et al., a high serum CRP, lymphopaenia, 
hypoalbuminaemia, respiratory failure, and 
mechanical ventilation are also associated with 
a poor prognosis [18]. Most of these factors were 
present in our patient and may have contributed 
to the fatal outcome. 
In conclusion, we advise caution in the use of 
leflunomide in RA patients with prior methotrexa-
te therapy or pre-existing interstitial lung disease, 
because of the elevated risk of lung injury, a rare 
but potentially life-threatening condition. There 
is need for an effective diagnostic and treatment 
algorithm to improve the final outcome in patients 
with leflunomide-induced lung injury. 
Polish Pneumonology and Allergology 2015, vol. 83, no. 1, pages 50–54 
54 www.pneumonologia.viamedica.pl
Conflict of interest
The authors declare no conflict of interest.
References
1. Kelly C., Hamilton J. What kills in rheumatoid arthritis? Rheu-
matology 2007; 46: 183−184.
2. Fox R., Helfgott S.M. Leflunomide in the treatment of rheuma-
toid arthritis. Up-to-Date 2013, www.uptodate.com
3. Sawada T., Inokuma S., Sato T. et al. Leflunomide-induced in-
terstitial lung disease: prevalence and risk factors in Japanese 
patients with rheumatoid arthritis. Rheumatology 2009; 48: 
1069−1072.
4. Young A., Koduri G., Batley M. et al. Mortality in rheumatoid 
arthritis. Increased in the early course of disease, in ischaemic 
heart disease and in pulmonary fibrosis. Rheumatology 2007; 
46: 350−357.
5. Tsuchiya Y., Takayanagi N., Sugiura H. et al. Lung diseases 
directly associated with rheumatoid arthritis and their rela-
tionship to outcome Eur. Respir. J. 2011; 37: 1411−1417.
6. Lake F.R. Drug-induced lung disease in rheumatoid arthritis. 
Up to Date 2013, www.uptodate.com
7. Bongartz T., Nannini C., Medina-Velasquez Y.F. Incidence 
and mortality of interstitial lung disease in rheumatoid ar-
thritis: a  population-based study. Arthritis Rheum. 2010; 62: 
1583−1591
8. Alcorn N., Saunders S., Madhok R. Benefit-risk assessment of 
leflunomide. An appraisal of leflunomide in rheumatoid ar-
thritis 10 years after licensing. Drug Saf. 2009; 32: 1123−1134.
9. McCurry J. Japan deaths spark concerns over arthritis drug. 
Lancet 2004, 363 (9407): 461. 
10. Ju J.H., Kim S.I., Lee J.H. et al. Risk of interstitial lung disease 
associated with leflunomide treatment in Korean patients with 
rheumatoid arthritis. Arthritis Rheum. 2007; 56: 2094−2096.
11. Suissa S., Hudson M., Ernst P. Leflunomide use and the risk 
of interstitial lung disease in rheumatoid arthritis. Arthritis 
Rheum. 2006; 54: 1435−1439.
12. Chikura B., Lane S., Dawson J.K. Clinical expression of le-
flunomide-induced pneumonitis. Rheumatology  2009; 48: 
1065−1068.
13. Ochi S., Harigai M., Mizoguchi F. et al. Leflunomide-related acute 
interstitial pneumonia in two patients with rheumatoid arthrtitis: 
autopsy findings with a mosaic pattern of acute and organizing 
diffuse alveolar damage. Mod. Rheumatol. 2006; 16: 316−320. 
14. Wong S.P., Chu C.M., Kan C.H. et al. Successful treatment of 
leflunomide-induced acute pneumonitis with cholestyramine 
wash-out therapy. J. Clin. Rheumatol. 2009; 15: 389−392.
15. Raj R., Nugent K. Leflunomide-induced interstitial lung dis-
ease (a systematic review). Sarcoidosis Vasc. Diffuse Lung Dis. 
2013; 30: 167−176. 
16. Kędziora K., Słomiński J.M., Gil K. et al. Inwazyjna grzybica 
kropidlakowa zatok przynosowych, płuc i  mózgowia. Pneu-
monol. Alergol. Pol. 2008; 76: 400–406. 
17. Beirao F., Araujo R. State of the art. Diagnostic of mold dis-
eases: a practical guide for clinicians. Eur. J. Clin. Microbiol. 
Infect. Dis. 2013; 32: 3–9.
18. Saito T., Inokuma S., Sagawa A. et al. Factors associated with 
fatal outcome of leflunomide-induced lung injury in Japanese 
patients with rheumatoid arthritis. Rheumatology 2009; 48: 
1265−1268.
